EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing an avian influenza vaccine using a novel Bacterial Enzymatic Combinatorial Chemistry (BECC) TLR4 adjuvant

Devon V Riley iD, Lauren Baracco, Sayan Das, Brandon M Tenaglia, Sydney Speed, Carly Dillen, Juliahna Hayes, Samanta Del Veliz, Haye Nijhuis, Valerie Le Sage, Hannah W Despres, Lynda Coughlan iD und 3 weitere

mSphere · 28.07.2026 · 11 (7)

DOI: 10.1128/msphere.00171-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSphere, erschienen am 28.07.2026. Verfasst von Devon V Riley und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza A Virus, H5N1 Subtype, Toll-Like Receptor 4, Adjuvants, Immunologic. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, ODCDC CDC HHS, U.S. Army.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of broadly protective and dose-sparing influenza vaccines remains a critical challenge, particularly for zoonotic H5N1 strains with pandemic potential. This study evaluates BECC470s, a synthetic TLR4 adjuvant, for its ability to enhance the immunogenicity and protective efficacy of recombinant H5 hemagglutinin (rHA) vaccination in murine models. BECC470s-adjuvanted rHA elicited robust IgG1/IgG2a antibody responses and complete survival following homologous 2004 H5N1 challenge in a prime–boost model. Although BECC470s broadened antibody binding to both variable HA head and conserved stalk domains by ELISA, functional neutralizing antibody responses were restricted to the matched 2004 H5N1 isolate, with no detectable neutralization of H5N1 viruses isolated in 2022 or 2024. These data indicate that BECC470s enhances the magnitude and apparent cross-reactivity of binding antibody responses while maintaining strain-specific neutralizing activity, supporting its potential as an adjuvant for next-generation influenza vaccines while underscoring the need for further optimization to achieve true cross-neutralizing protection. IMPORTANCE BECC470s is a synthetic TLR4 agonist adjuvant that enhances the breadth and potency of recombinant H5 hemagglutinin vaccination in mice. By driving balanced antibody responses, complete protection against homologous challenge, and neutralizing activity targeting both HA head and stalk, BECC470s outperforms the comparator TLR4 adjuvant. These preliminary findings indicate that BECC470s enables antigen sparing while increasing antigen immunogenicity, supporting its potential translational application to current H5N1 vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza A Virus, H5N1 SubtypeToll-Like Receptor 4Adjuvants, ImmunologicAdjuvants, VaccineAnimalsAntibodies, ViralMiceAntibodies, NeutralizingHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin GOrthomyxoviridae InfectionsFemaleMice, Inbred BALB CVaccination

Stichwörter der Autor:innen

adjuvantsavian virusesinfluenza vaccines

Substanzen

Influenza VaccinesAntibodies, ViralToll-Like Receptor 4Adjuvants, ImmunologicAntibodies, NeutralizingHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin GAdjuvants, VaccineTlr4 protein, mouse

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland, USA.
  • Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, Maryland, USA.
  • Center for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Center for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Devon V Riley, Lynda Coughlan, Weina Sun, Matthew B Frieman, Robert K Ernst

Förderung

  • NIH HHS
  • ODCDC CDC HHS
  • U.S. Army
  • NINR NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Riley, D. V., Baracco, L., Das, S., Tenaglia, B. M., Speed, S., Dillen, C., Hayes, J., Del Veliz, S., Nijhuis, H., Le Sage, V., Despres, H. W., Coughlan, L., Sun, W., Frieman, M. B., & Ernst, R. K. (2026). Optimizing an avian influenza vaccine using a novel Bacterial Enzymatic Combinatorial Chemistry (BECC) TLR4 adjuvant. mSphere, 11(7). https://doi.org/10.1128/msphere.00171-26

Vancouver

Riley DV, Baracco L, Das S, Tenaglia BM, Speed S, Dillen C, et al. Optimizing an avian influenza vaccine using a novel Bacterial Enzymatic Combinatorial Chemistry (BECC) TLR4 adjuvant. mSphere. 2026;11(7). doi:10.1128/msphere.00171-26

BibTeX
@article{Riley2026,
  author = {Riley, Devon V and Baracco, Lauren and Das, Sayan and Tenaglia, Brandon M and Speed, Sydney and Dillen, Carly and Hayes, Juliahna and Del Veliz, Samanta and Nijhuis, Haye and Le Sage, Valerie and Despres, Hannah W and Coughlan, Lynda and Sun, Weina and Frieman, Matthew B and Ernst, Robert K},
  title = {Optimizing an avian influenza vaccine using a novel Bacterial Enzymatic Combinatorial Chemistry (BECC) TLR4 adjuvant},
  journal = {mSphere},
  year = {2026},
  volume = {11},
  number = {7},
  doi = {10.1128/msphere.00171-26}
}
Kostenlos starten →